Alterity Therapeutics (ASXATH) has unveiled a new commercial assessment of its lead candidate ATH434, positioning the therapy as a potential first-in-class treatment for Multiple System Atrophy, a rare and debilitating Parkinsonian disorder with no approved therapies. …
Alterity Therapeutics targets major market with ATH434 in Multiple System Atrophy
September 29, 2025 Australian Biotech
Latest Video
New Stories
-
An institution dominated by very clever people, but where is the wisdom?
August 14, 2026 - - Latest News -
A plain language version of these dreadful and useless documents
August 14, 2026 - - Latest News -
CUREator+ backs six Australian startups with $13.5 million to advance new health technologies
August 13, 2026 - - Australian Biotech -
Medicines Australia appoints former AbbVie executive to key leadership role
August 13, 2026 - - Latest News -
VVMF and Optosleep partner to advance Australian gene therapy for sleep apnoea
August 13, 2026 - - Latest News -
Survey exposes deep gaps in neurological care across Australia
August 13, 2026 - - Latest News -
Australia 'is not an island' on pricing and we cannot be so arrogant to expect free product
August 13, 2026 - - Latest News